Navigation Links
Par Pharmaceutical Reports EPS of $0.71 for Second Quarter 2009
Date:8/4/2009

WOODCLIFF LAKE, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported results for the second quarter ended June 27, 2009.

For the second quarter ended June 27, 2009, Par reported total revenues of $404.0 million and net income of $23.8 million, or $0.71 per diluted share, which included a one-time gain related to the acquisition of certain assets of MDRNA's Hauppauge, NY facility. Adjusting for this item, earnings per diluted share were $0.65 for the three month period ended June 27, 2009. This is compared to reported revenues of $112.9 million and a net loss of $21.2 million, or $0.64 loss per diluted share for the same period in 2008, which included a one-time development milestone payment to a partner. Adjusting for this item, loss per diluted share was $0.61 for the three month period ended June 28, 2008.

For the six months ended June 27, 2009, total revenue was $608.0 million with net income of $39.9 million, or $1.18 per diluted share. This is compared to total revenues of $267.9 million and a net loss of $19.8 million, or $0.60 per diluted share in the same period of 2008.

Second Quarter Highlights

Key Product Sales (Net sales comparisons at the product level are to first quarter 2009)

  • Metoprolol: For the quarter ended June 27, 2009, net sales of metoprolol succinate reached $306 million, an increase of 173% from the first quarter 2009. The increase was driven by market exclusivity and additional product supply which led to increased volume and price. Par remained the exclusive supplier of metoprolol succinate through the second quarter. Par is the authorized generic for all strengths of AstraZeneca's Toprol(R) XL.


    '/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
2. Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
3. Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics: From Concept to Implementation Conference
4. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
5. MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Settlement of Ethyol(R) ANDA Patent Litigation
7. Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for KRYSTEXXA(TM)
8. Transcept Pharmaceuticals to Hold Conference Call on Agreement with Purdue Pharmaceutical Products L.P. to Commercialize Intermezzo(R) in the United States
9. Excaliard Pharmaceuticals Appoints Jay Birnbaum, Ph.D. to the Board of Directors.
10. Arena Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference
11. Growth in Personalized Medicine to Drive Alliances Between Diagnostics and Pharmaceutical Industries, According to PricewaterhouseCoopers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014 The first ORTC Public ... Microsoft, and Google. ( http://ortc.org/wp-content/uploads/2014/08/ortc.html ) , ... to create a WebRTC 1.1 API with exceptional ... WebRTC, ORTC (Object Real-time Communication) enables plugin-free real-time ... specifically tailored to provide the direct control needed ...
(Date:8/22/2014)... 22, 2014 The Berkowitz Law Firm ... a client who suffered severe, permanent injuries in an ... driver (docket number FST-CV13-6018309-S). The case was pending in ... According to Jennifer Amdur of The Berkowitz Law Firm ... all of whom were allegedly injured following ...
(Date:8/22/2014)... FastFingerprints is adding a new location to ... Wednesday, August 27, 2014 and is located at 3740 ... the addition of this new office, that will bring ... Cleveland area. Our new Cleveland-Midtown location will provide ... hours of operation will be Monday-Friday 8:00am – 5:00pm ...
(Date:8/22/2014)... 22, 2014 Teen substance abuse has ... OH. Unfortunately, most young adults never receive the professional ... the community, the new Troubled Teens Columbus helpline was ... to overcome their drug and alcohol dependencies . ... teens and their parents can speak directly to a ...
(Date:8/22/2014)... 2014 Dr Murray Grossan was interviewed for ... , In the October 2014 issue of Bottom Line Personal ... his method of treating snoring, and in some cases Obstructive ... half of all adults snore occasionally, and about 25% do ... air passages in the back of the throat tend to ...
Breaking Medicine News(10 mins):Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 2Health News:Hookflash, Google and Microsoft lead on ORTC / WebRTC 1.1 Public Draft 3Health News:The Berkowitz Law Firm LLC Reaches a $2 Million Settlement for a Client Allegedly Injured in Drunk Driving Accident 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 2Health News:FastFingerprints Expands In The Cleveland Ohio Area 3Health News:New Helpline in Columbus Assists Troubled Teen Find Youth Rehab 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 2Health News:Dr Murray Grossan Explains how and why Singing Exercises Stop Snoring 3
... VNDA ) ("Vanda" or the "Company") announced today ... contest by withdrawing its nominations of director candidates for election ... liquidate the Company. TCP had previously notified the Company of ... of its candidates to the Vanda Board at the Company,s ...
... is National Lupus Awareness MonthWASHINGTON, May 7 ... risks associated with breast cancer and heart disease, but ... aware of another potentially fatal disease that disproportionately strikes ... The disease is lupus.Although more than 1.5 million ...
... May 7 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") ... pharmaceutical products in China, today,announced that it plans to ... 2009, before the market opens. , ... 8:00 am ET on May 15, 2009 to,discuss fiscal ...
... (NYSE: MTD ) today announced the webcast of its ... Conference in New York on Thursday, May 14, 2009, at 10:40 ... presentation, visit the investor relations page on the Company,s Web site ... /investors . A replay of the webcast will be ...
... Recent scientific studies published in the medical journals ... Journal of Nutrition, and others, showed that the ... anti-cancer activities. Gene-Eden is a dietary supplement ... unique, patent-pending formulation. Gene-Eden was introduced in February ...
... Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on ... results for the three month period ended March 31, 2009. ... in the first quarter of 2008. The net loss for ... diluted share, compared to a net loss of $762,000, or ...
Cached Medicine News:Health News:Vanda Pharmaceuticals Announces Withdrawal of Director Nominees and Proposal to Liquidate Submitted by Tang Capital 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 2Health News:Public Lacks Awareness of Serious Disease With Life-Threatening Complications 3Health News:China Pharma Holdings, Inc. to Report First Quarter 2009 Financial Results on May 15, 2009 2Health News:The Center for the Biology of Chronic Disease Highlights Anti-Cancer Activities of the Food Extracts Quercetin, EGCG, Glycyrrhizin, and Trans-Cinnamaldehyde 2Health News:PLC Systems Reports First Quarter 2009 Results 2Health News:PLC Systems Reports First Quarter 2009 Results 3Health News:PLC Systems Reports First Quarter 2009 Results 4Health News:PLC Systems Reports First Quarter 2009 Results 5
(Date:8/21/2014)... Aug. 21, 2014 Asterias Biotherapeutics, Inc. (OTCBB: ... of regenerative medicine, announced today the appointments of Andrew ... newly expanded Board of Directors. With these additions, the ... of whom are independent. Andy Arno ... emerging growth companies. He is currently Managing Director of ...
(Date:8/20/2014)... Aug. 20, 2014  The National Association of ... results achieved by the real-time, pseudoephedrine (PSE) blocking ... Precursor Log Exchange (NPLEx), automatically blocks unlawful PSE ... meth offenders and make arrests. Data released by ... blocked the sale of more than ...
(Date:8/20/2014)... 20, 2014  The National Association of Drug ... achieved by the real-time, pseudoephedrine (PSE) blocking system ... Log Exchange (NPLEx), automatically blocks unlawful pseudoephedrine sales ... offenders and make arrests. Data released by NPLEx ... blocked the sale of more than 19,030 ...
Breaking Medicine Technology:Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2Missouri's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
Standard Deflectable Catheters...
The Explorer ST "soft tip" catheter has a proximal shaft with a soft tip. It is available in both a 5F and 6F shaft configuration....
... offers a wide range of deflectable curve ... needs of children and other patients with ... demanding specifications using only the finest materials. ... wire braiding and extrusion technologies results in ...
A-Focus I & II Catheters. A-Focus steerable atrial mapping catheter. Available in 10, 12, 14 and 20 electrode configurations. (Shown with 14 electrodes)....
Medicine Products: